191 related articles for article (PubMed ID: 16871471)
21. [Successful treatment of depression in a Parkinson disease patient with bupropion].
Leentjens AF; Verhey FR; Vreeling FW
Ned Tijdschr Geneeskd; 2000 Nov; 144(45):2157-9. PubMed ID: 11086491
[TBL] [Abstract][Full Text] [Related]
22. Psychotropic treatment of chronic fatigue syndrome and related disorders.
Goodnick PJ; Sandoval R
J Clin Psychiatry; 1993 Jan; 54(1):13-20. PubMed ID: 8428892
[TBL] [Abstract][Full Text] [Related]
23. Induction of a mixed depressive episode during rTMS treatment in a patient with refractory major depression.
Rachid F; Golaz J; Bondolfi G; Bertschy G
World J Biol Psychiatry; 2006; 7(4):261-4. PubMed ID: 17071547
[TBL] [Abstract][Full Text] [Related]
24. Psychopharmacology of smoking cessation in patients with mental illness.
Selby P
J Psychiatry Neurosci; 2006 Sep; 31(5):360. PubMed ID: 16951737
[No Abstract] [Full Text] [Related]
25. Model-based approach and signal detection theory to evaluate the performance of recruitment centers in clinical trials with antidepressant drugs.
Merlo-Pich E; Gomeni R
Clin Pharmacol Ther; 2008 Sep; 84(3):378-84. PubMed ID: 18449185
[TBL] [Abstract][Full Text] [Related]
26. Combined bupropion-levodopa-trazodone therapy of sleep-related eating and sleep disruption in two adults with chemical dependency.
Schenck CH; Mahowald MW
Sleep; 2000 Aug; 23(5):587-8. PubMed ID: 10947025
[No Abstract] [Full Text] [Related]
27. Increased serum IgM antibodies directed against phosphatidyl inositol (Pi) in chronic fatigue syndrome (CFS) and major depression: evidence that an IgM-mediated immune response against Pi is one factor underpinning the comorbidity between both CFS and depression.
Maes M; Mihaylova I; Leunis JC
Neuro Endocrinol Lett; 2007 Dec; 28(6):861-7. PubMed ID: 18063934
[TBL] [Abstract][Full Text] [Related]
28. Using psychostimulants for treating residual symptoms in major depression.
Berlim MT; Turecki MG
J Psychiatry Neurosci; 2007 Jul; 32(4):304. PubMed ID: 17653297
[No Abstract] [Full Text] [Related]
29. Tardive dyskinesia associated with long-term administration of escitalopram and itopride in major depressive disorder.
Park YM; Lee HJ; Kang SG; Choo CS; Cho JH
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):380-1. PubMed ID: 19121360
[No Abstract] [Full Text] [Related]
30. Suicidal ideation declines with improvement in the subjective symptoms of major depression.
Keilp JG; Ellis SP; Gorlyn M; Burke AK; Oquendo MA; Mann JJ; Grunebaum MF
J Affect Disord; 2018 Feb; 227():65-70. PubMed ID: 29053977
[TBL] [Abstract][Full Text] [Related]
31. A twin study of cognitive function in chronic fatigue syndrome: the effects of sudden illness onset.
Claypoole KH; Noonan C; Mahurin RK; Goldberg J; Erickson T; Buchwald D
Neuropsychology; 2007 Jul; 21(4):507-13. PubMed ID: 17605583
[TBL] [Abstract][Full Text] [Related]
32. Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder.
Stahl SM; Zhang L; Damatarca C; Grady M
J Clin Psychiatry; 2003; 64 Suppl 14():6-17. PubMed ID: 14658930
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis.
Ehde DM; Kraft GH; Chwastiak L; Sullivan MD; Gibbons LE; Bombardier CH; Wadhwani R
Gen Hosp Psychiatry; 2008; 30(1):40-8. PubMed ID: 18164939
[TBL] [Abstract][Full Text] [Related]
34. Does depression mediate the relation between fatigue severity and disability in chronic fatigue syndrome sufferers?
Hadlandsmyth K; Vowles KE
J Psychosom Res; 2009 Jan; 66(1):31-5. PubMed ID: 19073290
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants.
Pae CU; Marks DM; Patkar AA; Masand PS; Luyten P; Serretti A
Expert Opin Pharmacother; 2009 Jul; 10(10):1561-70. PubMed ID: 19514866
[TBL] [Abstract][Full Text] [Related]
36. Alexithymia in chronic fatigue syndrome: associations with momentary, recall, and retrospective measures of somatic complaints and emotions.
Friedberg F; Quick J
Psychosom Med; 2007 Jan; 69(1):54-60. PubMed ID: 17244849
[TBL] [Abstract][Full Text] [Related]
37. Time course of response to paroxetine: influence of plasma level.
Gex-Fabry M; Gervasoni N; Eap CB; Aubry JM; Bondolfi G; Bertschy G
Prog Neuropsychopharmacol Biol Psychiatry; 2007 May; 31(4):892-900. PubMed ID: 17395353
[TBL] [Abstract][Full Text] [Related]
38. Open, uncontrolled, nonrandomized, 9-month, off-label use of bupropion to treat fatigue in a single patient with multiple sclerosis.
Siniscalchi A; Gallelli L; Tolotta GA; Loiacono D; De Sarro G
Clin Ther; 2010 Nov; 32(12):2030-4. PubMed ID: 21118738
[TBL] [Abstract][Full Text] [Related]
39. Bupropion-induced neck and shoulder pain.
Sansone RA; Sansone LA
Pharmacopsychiatry; 2009 Sep; 42(5):203-4. PubMed ID: 19724984
[No Abstract] [Full Text] [Related]
40. Bupropion in the management of apathy.
Corcoran C; Wong ML; O'Keane V
J Psychopharmacol; 2004 Mar; 18(1):133-5. PubMed ID: 15107198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
